DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics (“DTx”) market, will be joining the broad-market Russell 3000(R) Index and the small-cap Russell 2000(R) Index at the conclusion of the Russell U.S. Indexes annual reconstitution, which will be effective after the U.S. equity markets open on Monday, June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on June 4, 2021. The annual reconstitution of the Russell indexes identifies the 4,000 largest U.S. stocks as of May 7, 2021; it also ranks them by total market capitalization. Once a company joins the Russell 3000 Index, the membership lasts for one year, until the index conducts its annual reconstitution. Membership in the index also includes automatic inclusion in the large-cap Russell 1000(R) Index or small-cap Russell 2000 Index along with appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes by evaluating market-capitalization rankings and style attributes. “Inclusion in the Russell indexes reflects the hard work and achievements of the entire Dario team as we work to build the premier digital health and therapeutics company,” said DarioHealth CEO Erez Raphael in the press release. “We look forward to a heightened awareness of our company that inclusion in these widely-followed indexes confers.”
To view the full press release, visit https://ibn.fm/srbgi
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. Dario’s next-generation, AI-powered, digital therapeutic solutions support more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software and coaching to help individuals improve health and sustain meaningful outcomes. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The company’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. Dario makes the right thing to do the easy thing to do. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.